The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Lucence Diagnostics
Patents, Royalties, Other Intellectual Property - Lucence Diagnostics
A multigene expression score for predicting response to anti-PD-1/PD-L1 therapy for clear cell renal cell cancer patients.
 
Yukti Choudhury
No Relationships to Disclose
 
Kai Wei Tan
No Relationships to Disclose
 
Hui Shan Tan
No Relationships to Disclose
 
Jian Cheng Hong
No Relationships to Disclose
 
Miah Hiang Tay
Employment - OncoCare Cancer Centre
 
Min-Han Tan
Employment - Lucence Diagnostics
Leadership - Lucence Diagnostics
Stock and Other Ownership Interests - Lucence Diagnostics
Research Funding - Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Drug delivery technology, diagnostics technology
 
Puay Hoon Tan
Patents, Royalties, Other Intellectual Property - Singhealth
 
Wan Ling Tan
No Relationships to Disclose
 
Quan Sing Ng
No Relationships to Disclose
 
Chee Keong Toh
No Relationships to Disclose
 
Ravindran Kanesvaran
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Janssen; MSD Oncology; Novartis
Consulting or Advisory Role - Astellas Pharma; Mundipharma; Novartis; pfizer
Research Funding - Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; MSD Oncology